| Literature DB >> 6178915 |
K De Ceulaer, C Gruber, R Hayes, G R Serjeant.
Abstract
The haematological and clinical effects of medroxyprogesterone acetate in homozygous sickle-cell (SS) disease were assessed in a 2-year controlled crossover trial completed by 23 patients. Haematological indices remained steady during the placebo phase, but during the medroxyprogesterone-acetate phase fetal haemoglobin, total haemoglobin, red-cell mass, and red-cell survival rose significantly, and reticulocytes, irreversibly-sickled-cell counts, and total bilirubin fell significantly. Painful crises were significantly less frequent during the medroxyprogesterone-acetate than the placebo phase. These results are compatible with an inhibition of in-vivo sickling in patients with SS disease during medroxyprogesterone-acetate treatment. The mechanisms of such an effect require further study.Entities:
Keywords: Americas; Biology; Bleeding; Caribbean; Contraception; Contraceptive Agents, Female; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--administraction and dosage; Contraceptive Agents--side effects; Contraceptive Methods; Depo-provera--administraction and dosage; Depo-provera--side effects; Developing Countries; Family Planning; Hematological Effects--analysis; Hemic System; Hemoglobin Level--analysis; Injectables; Jamaica; Medroxyprogesterone Acetate--administraction and dosage; North America; Pain; Physiology; Reproductive Control Agents
Mesh：
Substances：
Year: 1982 PMID： 6178915 DOI： 10.1016/s0140-6736(82)90320-8
Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321